China is now the world’s second-largest market for pharmaceuticals, and the government is prioritizing the development of the country’s life science sector as a strategy for both improving public health and fostering economic growth. This NBR Special Report examines China’s efforts to create a globally competitive environment for life science innovation and assesses the implications for industry and policy.